{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:50:25Z","timestamp":1663141825370},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10585-022-10181-8","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T14:06:08Z","timestamp":1659449168000},"page":"711-711","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro\u2010intestinal peritoneal metastases in laboratory animals: a systematic review"],"prefix":"10.1007","volume":"39","author":[{"given":"J.-Matthias","family":"L\u00f6hr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"10181_CR1","doi-asserted-by":"publisher","unstructured":"Wintjens A, Simkens GA, Fransen PKH et al (2022) Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro-intestinal peritoneal metastases in laboratory animals: a systematic review. Clin Exp Metastasis. https:\/\/doi.org\/10.1007\/s10585-022-10173-8","DOI":"10.1007\/s10585-022-10173-8"},{"key":"10181_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101676","volume":"40","author":"H Abdel Mageed","year":"2022","unstructured":"Abdel Mageed H, Van Der Speeten K, Sugarbaker P (2022) The many faces of intraperitoneal chemotherapy. Surg Oncol 40:101676","journal-title":"Surg Oncol"},{"key":"10181_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pan.2012.11.305","volume":"13","author":"V Yagublu","year":"2013","unstructured":"Yagublu V, Caliskan N, Lewis AL et al (2013) Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads. Pancreatology 13:79\u201387","journal-title":"Pancreatology"},{"key":"10181_CR4","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/ijc.24211","volume":"124","author":"M Keese","year":"2009","unstructured":"Keese M, Gasimova L, Schwenke K et al (2009) Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. Int J Cancer 124:2701\u20132708","journal-title":"Int J Cancer"},{"key":"10181_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/sj.cgt.7700849","volume":"13","author":"S Samel","year":"2006","unstructured":"Samel S, Keese M, Lux A et al (2006) Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther 13:65\u201373","journal-title":"Cancer Gene Ther"},{"key":"10181_CR6","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(00)04749-8","volume":"357","author":"M L\u00f6hr","year":"2001","unstructured":"L\u00f6hr M, Hoffmeyer A, Kroger J et al (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357:1591\u20131592","journal-title":"Lancet"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-022-10181-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:22:37Z","timestamp":1663140157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-022-10181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10181"],"URL":"https:\/\/doi.org\/10.1007\/s10585-022-10181-8","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I am on the board of directors of PharmaCyte Biotech Inc., the company developing the CYP2B1 encapsulated cell therapy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}